Cerba Healthcare, headquartered in France and firmly established in Europe and Africa through its historical routine and specialty biology expertise, also operates globally through its clinical trials business unit for the validation of new compounds and vaccines. It stands as a unique group in the diagnosis market, covering the needs for diagnostic tools and expertise for patients, physicians, hospitals and the pharmaceutical industry.
With this new partnership, Cerba HealthCare reinforces its capital structure with its existing shareholders -more than 400 long-time biologists and managers- and its long-term partner, PSP Investments, to sustain the Group's development strategy and current transformation.
Catherine Courboillet, CEO, Cerba HealthCare, states: "Over the past four years, Partners Group has shown a comprehensive understanding of our market and unwavering support in sustaining Cerba HealthCare's growth strategy. In order to continue to fulfill the Group's long-term development, we are excited to welcome a partner that shares the same vision and values, as well as a strong understanding of the importance of cutting-edge, personalized services. It is critical to keep on investing heavily in innovation, IT security and talents in order to drive further and faster our on-going transformationtowards better healthcare services for patients. With EQT, we have chosen an experienced partner that will strengthen our European positioning while helping us expand into new markets."
Nicolas Brugre, Partner, Investment Advisor at EQT Partners and Head of EQT France, comments:"EQT has followed Cerba HealthCare for a long time and we are deeply impressed with the company's unique platform for medical diagnoses and superior scientific expertise. Cerba HealthCare is a purpose-driven company with a culture that is well-aligned with EQT's values and we are happy to partner with its management team and with PSP Investments. EQT Private Equity is committed to invest in and future-proof Cerba HealthCare for the long-run to best serve patients and healthcare professionals."
Kim Nguyen, Partner, Private Equity Services, Partners Group, adds: "Cerba HealthCare operates in an important sector and we are proud to have successfully contributed to the sustainable growth strategy of the Company over the last four years. In line with Partners Group's focus on positive stakeholder impact and entrepreneurial governance, Cerba HealthCare has not wavered in its commitment to responding to the COVID-19 crisis. During our holding period, the Company has transformed into a market leader, penetrating new international markets, including in Africa and Italy, further consolidating its expertise in clinical trials and securing leadership in the veterinary biology sector. We are convinced Cerba HealthCare is poised for lasting success and that, after our strong and collaborative partnership, it is the right time and opportunity for all stakeholders that the Company move into its next phase of growth."
Simon Marc, Senior Managing Director and Global Head of Private Equity, PSP Investments, said: "Since our initial partnership with Cerba HealthCare in 2017, the company has gone from strength to strength, and we are excited to continue supporting Catherine and her talented management team as long term-partners. We look forward to welcoming EQT who has been one of PSP Investments core partners for many years, and who brings tremendous expertise in European healthcare. Together, we will provide the long-term strategic capital to support Cerba HealthCare in achieving its full potential through its next phase of development as a European leader in medical diagnostics."
Following the completion of the deal, which is subject to administrative notifications and regulatory approvals, EQT Private Equity and PSP Investments will work with Cerba HealthCare's management team, led by CEO Catherine Courboillet, to support the numerous growth opportunities of the business. These include the continuation of the Company's highly successful M&A strategy on a global scale, as well as the acceleration of organic growth and development in other segments.
About Cerba HealthCareCerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on 5 continents, the Group's 8500 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.Cerba HealthCare, enlightening health.
About PSP InvestmentsPSP Investments is one of Canada's largest pension investment managers with approximately $169.8 billion of net assets as of March 31, 2020. It manages a diversified global portfolio of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP Investments manages net contributions to the pension funds of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montreal and offices in New York, London and Hong Kong. For more information, visit investpsp.com or follow PSP Investments on Twitter and LinkedIn.
About Partners GroupPartners Group is a leading global private markets firm. Since 1996, the firm has invested over USD 145 billion in private equity, private real estate, private debt and private infrastructure on behalf of its clients globally. Partners Group is a committed, responsible investor and aims to create broad stakeholder impact through its active ownership and development of growing businesses, attractive real estate and essential infrastructure. With over USD 109 billion in assets under management as of 31 December 2020, Partners Group serves a broad range of institutional investors, sovereign wealth funds, family offices and private individuals globally. The firm employs more than 1,500 diverse professionals across 20 offices worldwide and has regional headquarters in Baar-Zug, Switzerland; Denver, USA; and Singapore. It has been listed on the SIX Swiss Exchange since 2006 (symbol: PGHN). For more information, please visit http://www.partnersgroup.comor follow us on LinkedInor Twitter.
About EQT EQT is a purpose-driven global investment organization with more than EUR 84 billion in raised capital and over EUR 52 billion in assets under management across 17 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and North America with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.More info: http://www.eqtgroup.com Follow EQT on LinkedIn, Twitter, YouTube and Instagram
Press contacts: Cerba Healthcare, Emmanuelle Saby, +33 6 09 10 76, [emailprotected]; PSP Investments, Maria Constantinescu, 1 844 525 3795, [emailprotected]; EQT, Brunswick Paris: Benoit Grange, (+ 33 6 14 45 09 26); Hugues Boton, (+33 6 79 99 27 15), [emailprotected]; Press contact EQT: [emailprotected]- +46 8 506 55 334; Partners Group, Jenny Blinch, +44207575 2571, [emailprotected]
SOURCE PSP Investments; Cerba Healthcare
- Personalized medicine could transform healthcare - PMC - April 24th, 2025
- Genomic medicine and personalized treatment: a narrative review - April 24th, 2025
- Podcast: Ochre Bios Approach To Precision Medicine In Liver Treatment - insights.citeline.com - April 24th, 2025
- Reinforcement Learning in Personalized Medicine: A Comprehensive Review of Treatment Optimization Strategies - Cureus - April 24th, 2025
- Evolving Biomarkers: Charting the Future of Precision Medicine - MarketScale - April 24th, 2025
- Next Generation Tissue Biomarkers Market Size Report 2030 - Grand View Research - April 24th, 2025
- City of Hope Research on Artificial Intelligence (AI), Precision Medicine, Immunotherapies and Other Topics to be Presented at American Association of... - April 24th, 2025
- What the Newest mRNA Vaccines Could Do Beyond COVID - News-Medical - April 24th, 2025
- Opinion: Where public health ends and personalised medicine begins - Pulse+IT News - April 24th, 2025
- Crohns Disease Treatment Market to Reach $5.9 Billion by 2034, Driven by Biologics & Precision Medicine - Global Banking | Finance | Review - April 24th, 2025
- The Role of High Throughput Screening in Precision Medicine and Market Growth In New Report - WhaTech - April 24th, 2025
- Antiviral Chewing Gum May Prevent Flu and Herpes Transmission - Inside Precision Medicine - April 14th, 2025
- Wisconsin's role in the next advances in health care - BizTimes - April 14th, 2025
- The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI - Managed Healthcare Executive - April 14th, 2025
- Leading Driver In The Jetrea Market 2025: Rise Of Personalized Medicine Fueling Growth - EIN News - March 9th, 2025
- Personalized Medicine Market Overview 2024-2025 & 2030: Oncology, Neurology, and Cardiology Lead Expansion, ext-Generation Sequencing and AI... - March 9th, 2025
- Innovations in core-shell nanoparticles advance drug delivery and precision medicine - Phys.org - March 9th, 2025
- Personalized Medicine: Motivation, Challenges and Progress - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - HealthLeaders Media - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - Fast Company - February 24th, 2025
- Artificial Intelligence (Ai) In Precision Medicine Market to See Robust Growth from USD 2.14 Billion to USD - EIN News - February 24th, 2025
- BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com - February 24th, 2025
- Cracking Cancers Code: How Genetic Testing Is Changing the Treatment Game - geneonline - February 24th, 2025
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022